Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Ranitidine for Improvement of Treatment-Resistant Psoriasis

Ranitidine for Improvement of Treatment-Resistant Psoriasis Abstract To the Editor.— Our studies of the effect of the histamine2 (H2) receptor antagonist, ranitidine, in patients with trauma- and blood transfusion-induced immunosuppression, in patients with multiple myeloma, and in patients with human immunodeficiency virus infection,1 have included a few patients with psoriatic lesions. Some of these patients who were treated with the active drug showed improvement in psoriatic disease, but with recurrence within a few weeks after the therapy was discontinued. Based on these observations, and despite previous randomized, placebo-controlled studies of short-term treatment (28 days) with another H2 receptor antagonist, cimetidine, which had shown no beneficial effect,2 an open pilot study of the effect of long-term (4 months) treatment with ranitidine in patients with different forms of psoriasis was initiated. Subjects and Methods.— Six patients were studied in the autumn of 1989 (September 1 through December 31, 1989). All of the patients had References 1. Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H. The potential impact of histamine-2 receptor antagonists as adjuvant therapy in colorectal cancer surgery: review . Acta Chir Scand. In press. 2. Long PR, Miller OF. Cimetidine and psoriasis . Arch Dermatol. 1981;117:523.Crossref 3. Rai GS, Webster SGP. Cimetidine and psoriasis . Lancet . 1979;1:50.Crossref 4. Giacosa A, Farris A, Cheli R. Cimetidine and psoriasis . Lancet . 1978;2:1211.Crossref 5. Merk H, Goerz G, Runne U, et al. Cimetidine and chlorpheniramine in the treatment of psoriasis . Dermatologica . 1983;166:94-96.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Ranitidine for Improvement of Treatment-Resistant Psoriasis

Ranitidine for Improvement of Treatment-Resistant Psoriasis

Abstract

Abstract To the Editor.— Our studies of the effect of the histamine2 (H2) receptor antagonist, ranitidine, in patients with trauma- and blood transfusion-induced immunosuppression, in patients with multiple myeloma, and in patients with human immunodeficiency virus infection,1 have included a few patients with psoriatic lesions. Some of these patients who were treated with the active drug showed improvement in psoriatic disease, but with recurrence within a few weeks after the therapy...
Loading next page...
 
/lp/american-medical-association/ranitidine-for-improvement-of-treatment-resistant-psoriasis-05UMXEgNfR
Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1991.01680020142028
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— Our studies of the effect of the histamine2 (H2) receptor antagonist, ranitidine, in patients with trauma- and blood transfusion-induced immunosuppression, in patients with multiple myeloma, and in patients with human immunodeficiency virus infection,1 have included a few patients with psoriatic lesions. Some of these patients who were treated with the active drug showed improvement in psoriatic disease, but with recurrence within a few weeks after the therapy was discontinued. Based on these observations, and despite previous randomized, placebo-controlled studies of short-term treatment (28 days) with another H2 receptor antagonist, cimetidine, which had shown no beneficial effect,2 an open pilot study of the effect of long-term (4 months) treatment with ranitidine in patients with different forms of psoriasis was initiated. Subjects and Methods.— Six patients were studied in the autumn of 1989 (September 1 through December 31, 1989). All of the patients had References 1. Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H. The potential impact of histamine-2 receptor antagonists as adjuvant therapy in colorectal cancer surgery: review . Acta Chir Scand. In press. 2. Long PR, Miller OF. Cimetidine and psoriasis . Arch Dermatol. 1981;117:523.Crossref 3. Rai GS, Webster SGP. Cimetidine and psoriasis . Lancet . 1979;1:50.Crossref 4. Giacosa A, Farris A, Cheli R. Cimetidine and psoriasis . Lancet . 1978;2:1211.Crossref 5. Merk H, Goerz G, Runne U, et al. Cimetidine and chlorpheniramine in the treatment of psoriasis . Dermatologica . 1983;166:94-96.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Feb 1, 1991

References